Twist Bioscience CEO Sells $919K in Stock via Rule 10b5-1 Plan

Insider Transaction Overview

On October 5, 2026, Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp ($TWST), executed open-market sales totaling 4,548 shares of common stock at a volume-weighted average price of $202.15 per share, generating approximately $919,373.66 in gross proceeds.

Transaction Details

The sales were reported across multiple tranches with weighted-average prices ranging from $200.44 to $207.46:

• 1,840 shares @ $200.4379
• 481 shares @ $201.2556
• 1,017 shares @ $202.3236
• 432 shares @ $203.6072
• 290 shares @ $204.7996
• 297 shares @ $205.7772
• 146 shares @ $206.8449
• 45 shares @ $207.4556

Holdings and Context

• Plan Details: The transactions were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan established on June 15, 2026.
• Remaining Ownership: Following these transactions, Dr. Leproust continues to directly hold 562,760 shares of common stock. Additionally, she holds options for 196,240 shares (131,290 at $23.33 exercise price and 64,950 at $67.85 exercise price).
• Market Impact & Significance: The disposition represents less than 1% of the insider's direct common stock holdings. Given that the sales were executed under an automated Rule 10b5-1 plan and represent a modest reduction relative to overall holdings, the trading significance is categorized as Low.